Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIGO Phase 3 study of obexelimab in IgG4-related disease
2022-500718-24-00Phase 3Authorised
- Sponsor
- Zenas BioPharma
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in IgG4-related disease (IgG4-RD) comparing Obexelimab with Placebo (2 arms). Primary endpoint: Time to first IgG4-related disease flare. Planned start Apr 2023; status: authorised.
02
Drugs
obexelimab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2022-500718-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500718-24-00.